Studies on the Synthesis of Pterdine Substituted Pyridonecarboxylic Acids as Potential Antibacterial Agents and their Antimicrobial Activities

항균제로서 Pteridine이 치환된 Pyridonecarboxylic Acids의 합성 및 항균 작용에 관한 연구

  • 류성렬 (대불대학교 화학공학과) ;
  • 주동준 (경희대학교 문리과대학 화학과)
  • Received : 1996.07.20
  • Accepted : 1996.11.15
  • Published : 1996.12.10


In order to synthesize a new antibacterial and antitumor agents, we have prepared new analogues pteroic acid(13a, 13b), which means C-9 position of pteroic acid has been replaced by norfloxacin(8) or ciprofloxacin(9) and amino group of C-2 position by $CH_3$. These derivatives were synthesized coupling at N-4 piperazine of norfloxacin and ciprofloxacin with 2-amino-3-cyano-5-chloromethylpyrazine(20) provided 1-alkyl(ethyl, cyclopropyl)-6-fluoro-1,4-dihydro-4-oxo-7-[[4-N-(2-amino-3-cyanopyrazin-5-yl)methyl]piperazin-1-yl]-3-quinoline-carboxylic acid(12a, 12b). It was then cyclized with acetamidine. HCI to obtain new analogues of C-2 desaminomethylpteroic acid(13a, 13b) in yield of 76.2% and 82.8 % respectively. These compounds were tested in vitro on antibacterial activity against Gram-positive and Gram-negative bacteria including Pseudomonas aeruginosa ATCC9027. In general, these synthesized compounds(13a, 13b) showed less potent activities than those of norfloxacin.



  1. Antimicrob. Agents Chemother. v.32 Potent Antipneumocystic and Antitoxoplasma Activities of Piritrexim, a Lipid-Soluble Antifolate J. A. Kovacs;C. A. Allegra.;J. C. Swan;J. C. Drake;J. E. Parrillo;B. A. Chabner;H. Masur
  2. J. Exp. Med. v.165 Activity of Aitifolates Against Pneumocystis carinii, Dihydrofolate Reductase and Identification of a Potent New Agent C. J. Allegra;J. A. Kovacs;J. C. Drake;J. C. Swan;B.A.Chabner;H. Masur
  3. Antimicrob. Agent Chemother v.35 Pnenmocystis carinii Dihydro folate Reductase Used to Screen Potential Antipneumocystis Drugs M. C. Broughton;S. F. Queener
  4. J. Am. Med. Assoc. v.266 Coat and Benefit of Secondary Prophylaxis for pneumocystis carinii pneumonia A. R. Castellano;M. D. Nettleman
  5. Experimental Chemistry v.Ⅳ R. J. Schnitzer;F. Hawking(ed.)
  6. Medicinal Chemistry(3rd ed.) R. M. Prinder;A. Burger(ed.)
  7. Med. Chem. v.29 Maryam Ghazala. M;G. Nair;Y. Gaumont;T. I. Kalam
  8. J. Am. Chem. Soc. v.69 D. R. Seeger;J. M. Smith;M. Hulquist
  9. J. Het. Chem. v.11 J. R. Piper;J. A. Montgomery
  10. proceeding of the forth International symposium on pteridine, Toba, 79(1969) Chemistry and biology of pteridine E. C. Taylor
  11. Proc. Am. Assoc. Cancer. Res. v.29 L. R. Hughes;P. R. Marsham;J. Oldfield;A. L. Jackman
  12. Eur. J. Med. Chem. v.19 V. Cecchettis;S. Dominich;A. Fravolini;F. Schiaffella
  13. Drug Design, Fact or Fantasy T. Fujita;G. Jolles(ed.);K. R. H. Wooldridge(ed.)
  14. J. Med. Chem. v.23 H. Koga;A. Itoh;S. Murayama;S. Suzue;T. Irikura
  15. Antimicrob. Ag. Chemother v.23 R. Wise(et al.)
  16. J. Med. Chem. v.27 J. Matsumoto;T. Miyamoto;A. Minamida;Y. Nishimura;H. Eqawa
  17. Sciences v.22 Drugs and Pharnaceutical E. J. Vandamme
  18. Org. Syn. Colleet. v.5 J. P Ferris;R. A. Sanchez;R. W. Mamcuso
  19. J. Org. Chem. v.40 E. C. Taylor;R. C. Rortnoy;D. C. Hochstetler
  20. Eur. J. Cancer. v.17 T. R. Jones;A. H. Calvert;A. L. Jackman;S. J. Brown;M. Jones;K. R. Harrap
  21. J. Antimicrob. Agents Chemother. v.23 R. Wise;J. M. Andrews;I. Edward